Abstract 318P
Background
The semi-dry dot-blot (SDB) method, a diagnostic procedure for detecting lymph node (LN) metastases using anti-cytokeratin (CK) antibody, is based on the theory that epithelial components such as CK are not found in normal LNs. Thus, metastases are diagnosed on basis of the presence of CK in lavage fluid of sectioned LNs. We prospectively evaluated novel SDB kits that use a newly developed anti-CK19 antibody and an automatic reader for diagnosing sentinel LN metastases in patients with breast cancer as a multi-center study.
Methods
We obtained 924 sentinel LNs dissected between January 2021 and December 2021 at six institutes in Japan. We excluded patients with neoadjuvant chemotherapy and neoadjuvant endocrine therapy. These LNs were sliced at 2-mm intervals and washed with PBS. Cells suspended in the lavage fluid of sliced LNs were centrifuged and lysed to extract protein. The extracted protein was applied to the SDB kit to diagnose LN metastasis using an automatic reader that evaluates absorbance. Washed LNs were blindly examined using intraoperative and permanent histological examination. Diagnoses based on SDB kit were compared with diagnoses made by permanent histological examination of the LNs. Primary endpoints were sensitivity, specificity, and overall agreement of the SDB kit for distinguishing macrometastases from non-macrometastases.
Results
Ninety-four of the 924 LNs were assessed as macrometastases, 40 as micrometastases and 790 as negative by histological examination. With a borderline CK19 absorbance of 11.9 milli-absorbance for detecting macrometastases with 0.989 Area Under the Curve, the sensitivity, specificity, and overall agreement of the SDB kit were 94.7%, 98.3%, and 97.9%, respectively. Furthermore, the kits and the automatic reader yielded diagnoses in approximately 20 min at a cost of less than 30 EUR for the SDB kit and less than 3,000 EUR for the automatic reader.
Conclusions
The kits with an automatic reader used in our study were accurate, quick, and cost-effective in diagnosing LN metastases without loss of LN tissue, and were especially useful for detecting distinguish macrometastases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Japan Agency for Medical Research and Development.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
282P - Analysis of Prosigna in hormone receptor-positive early-stage breast cancer cohort after 8 years of experience at a single institution
Presenter: DANIEL MORCHÓN ARAUJO
Session: Poster session 02
283P - Patient profiles treated with extended adjuvant neratinib in the early access registry study: NEAR study
Presenter: Michelino De Laurentiis
Session: Poster session 02
284P - Prognostic and predictive impact of uPA/PAI-1 in early breast cancer
Presenter: Vanessa Wieder
Session: Poster session 02
285P - Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study
Presenter: Stefania Morganti
Session: Poster session 02
286P - Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study
Presenter: Antonino Musolino
Session: Poster session 02
287P - Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
Presenter: Johan Staaf
Session: Poster session 02
288P - Prognostic factors in nonmetastatic HER2 ‘low’ & HER2 ‘negative’ breast cancer: Single institute experience
Presenter: Alper Türkel
Session: Poster session 02
289P - Results of the window-of-opportunity clinical trial D-BIOMARK: Study of biomarkers of the antitumor activity of denosumab and its role as a modulator of the immune response in early breast cancer
Presenter: Andrea Vethencourt
Session: Poster session 02
290P - Metabolomic profiling and response to neoadjuvant therapy (NAT) in early breast cancer (EBC)
Presenter: Alessandra Gennari
Session: Poster session 02
291P - Prognostic implications of HER2 gain in patients with HR+/HER2- breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)
Presenter: Emanuela Ferraro
Session: Poster session 02